JP2024155943A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024155943A5 JP2024155943A5 JP2024134780A JP2024134780A JP2024155943A5 JP 2024155943 A5 JP2024155943 A5 JP 2024155943A5 JP 2024134780 A JP2024134780 A JP 2024134780A JP 2024134780 A JP2024134780 A JP 2024134780A JP 2024155943 A5 JP2024155943 A5 JP 2024155943A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- polypeptide
- region
- cancer
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 19
- 229920001184 polypeptide Polymers 0.000 claims 14
- 102000004196 processed proteins & peptides Human genes 0.000 claims 14
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 9
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 8
- 239000000427 antigen Substances 0.000 claims 7
- 102000036639 antigens Human genes 0.000 claims 7
- 108091007433 antigens Proteins 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 125000006850 spacer group Chemical group 0.000 claims 5
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 4
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 230000000139 costimulatory effect Effects 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 108700012439 CA9 Proteins 0.000 claims 2
- -1 CD44v7/8 Proteins 0.000 claims 2
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims 2
- 108010009685 Cholinergic Receptors Proteins 0.000 claims 2
- 101150029707 ERBB2 gene Proteins 0.000 claims 2
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 claims 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 2
- 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 claims 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 2
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 2
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims 2
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 claims 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 2
- 102000003735 Mesothelin Human genes 0.000 claims 2
- 108090000015 Mesothelin Proteins 0.000 claims 2
- 102100034256 Mucin-1 Human genes 0.000 claims 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 2
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims 2
- 108010012255 Neural Cell Adhesion Molecule L1 Proteins 0.000 claims 2
- 102100024964 Neural cell adhesion molecule L1 Human genes 0.000 claims 2
- 102100036735 Prostate stem cell antigen Human genes 0.000 claims 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 2
- 102000034337 acetylcholine receptors Human genes 0.000 claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 2
- 230000001605 fetal effect Effects 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 230000036210 malignancy Effects 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 2
- 101150047061 tag-72 gene Proteins 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 210000003289 regulatory T cell Anatomy 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562248685P | 2015-10-30 | 2015-10-30 | |
| US62/248,685 | 2015-10-30 | ||
| JP2018522004A JP7104624B2 (ja) | 2015-10-30 | 2016-10-28 | トランスフォーミング増殖因子ベータ応答性ポリペプチド及びその使用方法 |
| PCT/US2016/059444 WO2017075433A1 (en) | 2015-10-30 | 2016-10-28 | Transforming growth factor-beta-responsive polypeptides and their methods for use |
| JP2022110653A JP7539434B2 (ja) | 2015-10-30 | 2022-07-08 | トランスフォーミング増殖因子ベータ応答性ポリペプチド及びその使用方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022110653A Division JP7539434B2 (ja) | 2015-10-30 | 2022-07-08 | トランスフォーミング増殖因子ベータ応答性ポリペプチド及びその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024155943A JP2024155943A (ja) | 2024-10-31 |
| JP2024155943A5 true JP2024155943A5 (enExample) | 2024-11-29 |
Family
ID=58631218
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018522004A Active JP7104624B2 (ja) | 2015-10-30 | 2016-10-28 | トランスフォーミング増殖因子ベータ応答性ポリペプチド及びその使用方法 |
| JP2022110653A Active JP7539434B2 (ja) | 2015-10-30 | 2022-07-08 | トランスフォーミング増殖因子ベータ応答性ポリペプチド及びその使用方法 |
| JP2024134780A Pending JP2024155943A (ja) | 2015-10-30 | 2024-08-13 | トランスフォーミング増殖因子ベータ応答性ポリペプチド及びその使用方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018522004A Active JP7104624B2 (ja) | 2015-10-30 | 2016-10-28 | トランスフォーミング増殖因子ベータ応答性ポリペプチド及びその使用方法 |
| JP2022110653A Active JP7539434B2 (ja) | 2015-10-30 | 2022-07-08 | トランスフォーミング増殖因子ベータ応答性ポリペプチド及びその使用方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11014980B2 (enExample) |
| EP (2) | EP3368571B1 (enExample) |
| JP (3) | JP7104624B2 (enExample) |
| KR (1) | KR102771979B1 (enExample) |
| CN (2) | CN108884155B (enExample) |
| DK (1) | DK3368571T5 (enExample) |
| ES (1) | ES2935372T3 (enExample) |
| FI (1) | FI3368571T3 (enExample) |
| HR (1) | HRP20230239T1 (enExample) |
| HU (1) | HUE061424T2 (enExample) |
| LT (1) | LT3368571T (enExample) |
| PL (1) | PL3368571T3 (enExample) |
| PT (1) | PT3368571T (enExample) |
| RS (1) | RS64053B1 (enExample) |
| SI (1) | SI3368571T1 (enExample) |
| SM (1) | SMT202300027T1 (enExample) |
| WO (1) | WO2017075433A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11384350B2 (en) | 2014-12-15 | 2022-07-12 | The Regents Of The University Of California | Cytotoxic molecules responsive to intracellular ligands for selective T cell mediated killing |
| SI3240805T1 (sl) | 2014-12-15 | 2025-04-30 | The Regents Of The University Of California | Bispecifični or-gate himerni antigenski receptor, odziv na cd19 in cd20 |
| SMT202300027T1 (it) * | 2015-10-30 | 2023-05-12 | Univ California | Polipeptidi sensibili al fattore di crescita trasformante beta e le loro modalità d’uso |
| EP3439698A1 (en) * | 2016-04-05 | 2019-02-13 | GlaxoSmithKline Intellectual Property Development Ltd | Inhibition of tgfbeta in immunotherapy |
| US11701384B2 (en) | 2016-09-02 | 2023-07-18 | The Regents Of The University Of California | Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments |
| CA3068550A1 (en) * | 2017-06-30 | 2019-01-03 | Kolon Life Science, Inc. | Pharmaceutical composition for preventing or treating osteoarthritis |
| CN109486745A (zh) * | 2017-09-12 | 2019-03-19 | 中国人民解放军第三军医大学第附属医院 | Fg-4592在促进表皮干细胞迁移方面的应用 |
| CN111684061B (zh) * | 2018-01-19 | 2024-07-30 | 美天施生物科技有限两合公司 | 表达嵌合抗原受体的调节性t细胞 |
| GB201807693D0 (en) * | 2018-05-11 | 2018-06-27 | Autolus Ltd | Cell |
| CN118546959A (zh) | 2019-03-05 | 2024-08-27 | 恩卡尔塔公司 | Cd19定向性嵌合抗原受体及其在免疫疗法中的用途 |
| JP2022545167A (ja) * | 2019-08-30 | 2022-10-26 | アロジーン セラピューティクス,インコーポレイテッド | Tgfベータ結合ドメインを含むキメラサイトカイン受容体 |
| CN111748043B (zh) * | 2020-07-03 | 2022-09-02 | 深圳市体内生物医药科技有限公司 | 一种嵌合抗原受体及其应用 |
| CA3193009A1 (en) * | 2020-08-26 | 2022-03-03 | The Regents Of The University Of California | Methods and compositions for treating glioblastoma |
| CN112500491B (zh) * | 2020-12-18 | 2022-04-08 | 深圳市迈加瑞生物技术有限公司 | 一种特异性中和辅助性T细胞TGF-β信号的双特异性抗体、其药物组合及其用途 |
| US20240336903A1 (en) * | 2021-08-19 | 2024-10-10 | Shandong Boan Biotechnology Co., Ltd. | Fusion Proteins for Dephosphorylating Proteins that Regulate T Cell Activation through the TCR Signaling Pathway |
| WO2023201206A1 (en) * | 2022-04-11 | 2023-10-19 | The Board Of Trustees Of The Leland Stanford Junior University | Cytokine adaptor proteins and uses thereof |
| EP4509522A1 (en) | 2023-08-16 | 2025-02-19 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | A tgfbeta switch receptor, a nucleic acid encoding it, cells and pharmaceutical compositions comprising the same |
| WO2025096419A1 (en) * | 2023-10-31 | 2025-05-08 | Lyell Immunopharma, Inc. | T cells comprising a chimeric antigen receptor targeting transforming growth factor beta and a t cell receptor targeting a tumor antigen, and use thereof |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| GB8725529D0 (en) | 1987-10-30 | 1987-12-02 | Delta Biotechnology Ltd | Polypeptides |
| JP2989002B2 (ja) | 1988-12-22 | 1999-12-13 | キリン―アムジエン・インコーポレーテツド | 化学修飾顆粒球コロニー刺激因子 |
| SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
| US5580737A (en) | 1990-06-11 | 1996-12-03 | Nexstar Pharmaceuticals, Inc. | High-affinity nucleic acid ligands that discriminate between theophylline and caffeine |
| US5543293A (en) | 1990-06-11 | 1996-08-06 | Nexstar Pharmaceuticals, Inc. | DNA ligands of thrombin |
| US5503978A (en) | 1990-06-11 | 1996-04-02 | University Research Corporation | Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US5631146A (en) | 1995-01-19 | 1997-05-20 | The General Hospital Corporation | DNA aptamers and catalysts that bind adenosine or adenosine-5'-phosphates and methods for isolation thereof |
| AU7274898A (en) | 1997-05-07 | 1998-11-27 | Bristol-Myers Squibb Company | Recombinant antibody-enzyme fusion proteins |
| US6492497B1 (en) | 1999-04-30 | 2002-12-10 | Cambridge Antibody Technology Limited | Specific binding members for TGFbeta1 |
| US7066469B2 (en) | 2002-08-06 | 2006-06-27 | University of Kentucky Research Foundation Board of Supervisors of Louisiana State University | Seal assembly for machinery housing |
| UA80296C2 (en) | 2002-09-06 | 2007-09-10 | Biogen Inc | Imidazolopyridines and methods of making and using the same |
| US20050125852A1 (en) * | 2003-05-09 | 2005-06-09 | Sugen, Inc. | Novel kinases |
| JP2007515949A (ja) | 2003-11-13 | 2007-06-21 | ジェネンテック・インコーポレーテッド | スクリーニングアッセイ及び腫瘍治療の方法 |
| MXPA06011199A (es) | 2004-03-31 | 2007-04-16 | Genentech Inc | Anticuerpos anti-tgf-beta humanizados. |
| EP1810980A1 (en) | 2004-10-28 | 2007-07-25 | Osaka University | Interleukin-6 inhibitors |
| EP1850873B1 (en) | 2005-02-08 | 2018-11-28 | Genzyme Corporation | Antibodies to tgfbeta |
| WO2007070866A2 (en) | 2005-12-16 | 2007-06-21 | Alcon, Inc. | Control of intraocular pressure using alk5 modulation agents |
| WO2009019441A2 (en) * | 2007-08-03 | 2009-02-12 | Asterion Limited | Granulocyte colony stimulating factor |
| TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| MY165160A (en) | 2010-09-01 | 2018-02-28 | Genzyme Corp | TREATMENT OF MYOCARDIAL INFARCTION USING TGF-ß ANTAGONISTS |
| EP4011913A1 (en) * | 2011-06-30 | 2022-06-15 | Chugai Seiyaku Kabushiki Kaisha | Heterodimerized polypeptide |
| EP3594245A1 (en) | 2012-02-13 | 2020-01-15 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| BR112015021595A2 (pt) | 2013-03-11 | 2017-10-10 | Genzyme Corp | anticorpos anti-tgf-beta engenheirados e fragmentos de ligação do antígeno |
| EP2986636B1 (en) * | 2013-04-17 | 2018-11-14 | Baylor College Of Medicine | Immunosuppressive tgf-beta signal converter |
| MX370272B (es) * | 2014-03-19 | 2019-12-09 | Cellectis | Receptores de antigeno quimerico especifico de cd123 para inmunoterapia de cancer. |
| CA2944528C (en) * | 2014-04-03 | 2021-08-10 | Cellectis | Cd33 specific chimeric antigen receptors for cancer immunotherapy |
| CA2945620C (en) * | 2014-04-14 | 2022-12-06 | Cellectis | Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy |
| SI3240805T1 (sl) | 2014-12-15 | 2025-04-30 | The Regents Of The University Of California | Bispecifični or-gate himerni antigenski receptor, odziv na cd19 in cd20 |
| US11384350B2 (en) | 2014-12-15 | 2022-07-12 | The Regents Of The University Of California | Cytotoxic molecules responsive to intracellular ligands for selective T cell mediated killing |
| SMT202300027T1 (it) * | 2015-10-30 | 2023-05-12 | Univ California | Polipeptidi sensibili al fattore di crescita trasformante beta e le loro modalità d’uso |
| KR20230148844A (ko) | 2016-03-29 | 2023-10-25 | 유니버시티 오브 써던 캘리포니아 | 암을 표적하는 키메라 항원 수용체 |
| CN108148863B (zh) | 2016-12-05 | 2019-12-17 | 上海优卡迪生物医药科技有限公司 | 一种封闭il6r的用于缓解crs的car-t转基因载体及其构建方法和应用 |
-
2016
- 2016-10-28 SM SM20230027T patent/SMT202300027T1/it unknown
- 2016-10-28 US US15/772,403 patent/US11014980B2/en active Active
- 2016-10-28 HU HUE16860930A patent/HUE061424T2/hu unknown
- 2016-10-28 HR HRP20230239TT patent/HRP20230239T1/hr unknown
- 2016-10-28 DK DK16860930.3T patent/DK3368571T5/da active
- 2016-10-28 ES ES16860930T patent/ES2935372T3/es active Active
- 2016-10-28 WO PCT/US2016/059444 patent/WO2017075433A1/en not_active Ceased
- 2016-10-28 KR KR1020187015353A patent/KR102771979B1/ko active Active
- 2016-10-28 RS RS20230155A patent/RS64053B1/sr unknown
- 2016-10-28 PL PL16860930.3T patent/PL3368571T3/pl unknown
- 2016-10-28 PT PT168609303T patent/PT3368571T/pt unknown
- 2016-10-28 CN CN201680077053.0A patent/CN108884155B/zh active Active
- 2016-10-28 EP EP16860930.3A patent/EP3368571B1/en active Active
- 2016-10-28 JP JP2018522004A patent/JP7104624B2/ja active Active
- 2016-10-28 EP EP22199829.7A patent/EP4169945A1/en active Pending
- 2016-10-28 CN CN202211444400.2A patent/CN115960264A/zh active Pending
- 2016-10-28 SI SI201631648T patent/SI3368571T1/sl unknown
- 2016-10-28 FI FIEP16860930.3T patent/FI3368571T3/fi active
- 2016-10-28 LT LTEPPCT/US2016/059444T patent/LT3368571T/lt unknown
-
2021
- 2021-05-18 US US17/323,568 patent/US20210277099A1/en active Pending
-
2022
- 2022-07-08 JP JP2022110653A patent/JP7539434B2/ja active Active
-
2024
- 2024-08-13 JP JP2024134780A patent/JP2024155943A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024155943A5 (enExample) | ||
| JP7781243B2 (ja) | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 | |
| May et al. | Advances in bispecific biotherapeutics for the treatment of cancer | |
| Thakur et al. | Cancer therapy with bispecific antibodies: Clinical experience | |
| Chen et al. | Bispecific antibodies in cancer immunotherapy | |
| JP2020103301A5 (enExample) | ||
| JP2020508334A5 (enExample) | ||
| Müller et al. | Bispecific antibodies | |
| US20190048085A1 (en) | Modified cells for immunotherapy | |
| WO2019005641A1 (en) | GUIDING AND NAVIGATION CONTROL PROTEINS AND METHODS OF PRODUCTION AND USE THEREOF | |
| FI3368571T3 (fi) | Transformoivia kasvutekijä-beeta-vasteellisia polypeptidejä ja niiden käyttömenetelmiä | |
| Moon et al. | Development of bispecific antibody for cancer immunotherapy: focus on T cell engaging antibody | |
| BR112019017629A2 (pt) | receptor de união ao antígeno, polinucleotídeo isolado, vetor, célula t transduzida, métodos para o tratamento de uma doença e para induzir a lise, utilização do receptor e receptor | |
| KR20050108349A (ko) | 영속적인 티 세포 반응을 유도하는 삼량체 폴리펩티드 구조물 | |
| IL271257B1 (en) | Multispecific antibodies and methods for their preparation and use | |
| JP7319250B2 (ja) | Strep-タグ特異的結合タンパク質およびその使用 | |
| Lum et al. | Targeting T cells with bispecific antibodies for cancer therapy | |
| Hayashi et al. | A highly effective and stable bispecific diabody for cancer immunotherapy: cure of xenografted tumors by bispecific diabody and T-LAK cells | |
| CA3237616A1 (en) | Improved antigen binding receptors | |
| A Baeuerle et al. | Clinical experience with gene therapy and bispecific antibodies for T cell-based therapy of cancer | |
| JP7025059B2 (ja) | CARライブラリおよびscFvの製造方法 | |
| JPWO2022170280A5 (enExample) | ||
| CN120112559A (zh) | 抗wt1/hla抗体及其应用 | |
| JPWO2021016585A5 (enExample) | ||
| CA3208891A1 (en) | Antibody-derived t cell activating technologies |